Yaoshibang, a Chinese pharmaceutical distribution platform, submitted an application on Tuesday for a public listing to the Hong Kong Stock Exchange (HKEx), with Goldman Sachs and CICC named as co-sponsors.
Starna Therapeutics, a Chinese firm focusing on the research and development of new mRNA drugs, recently announced the completion of round-A financing totaling 150 million yuan ($22.1 million).
